These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 31979079)

  • 21. Cost-effectiveness analysis of 10- and 13-valent pneumococcal conjugate vaccines in Peru.
    Mezones-Holguin E; Canelo-Aybar C; Clark AD; Janusz CB; Jaúregui B; Escobedo-Palza S; Hernandez AV; Vega-Porras D; González M; Fiestas F; Toledo W; Michel F; Suárez VJ
    Vaccine; 2015 May; 33 Suppl 1():A154-66. PubMed ID: 25919156
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.
    Vučina VV; Filipović SK; Kožnjak N; Stamenić V; Clark AD; Mounaud B; Blau J; Hoestlandt C; Kaić B
    Vaccine; 2015 May; 33 Suppl 1():A209-18. PubMed ID: 25919163
    [TBL] [Abstract][Full Text] [Related]  

  • 23. How cost effective is switching universal vaccination from PCV10 to PCV13? A case study from a developing country.
    Castañeda-Orjuela C; De la Hoz-Restrepo F
    Vaccine; 2018 Sep; 36(38):5766-5773. PubMed ID: 30087049
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Estimating the population health and economic impacts of introducing a pneumococcal conjugate vaccine in Malaysia- an economic evaluation.
    Shafie AA; Ahmad N; Naidoo J; Foo CY; Wong C; Pugh S; Tan KK
    Hum Vaccin Immunother; 2020 Jul; 16(7):1719-1727. PubMed ID: 31951782
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incidence of invasive pneumococcal disease before and during an era of use of three different pneumococcal conjugate vaccines in Quebec.
    De Wals P; Lefebvre B; Deceuninck G; Longtin J
    Vaccine; 2018 Jan; 36(3):421-426. PubMed ID: 29224962
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness of the seven-valent and thirteen-valent pneumococcal conjugate vaccines in England: The indirect cohort design, 2006-2018.
    Andrews N; Kent A; Amin-Chowdhury Z; Sheppard C; Fry N; Ramsay M; Ladhani SN
    Vaccine; 2019 Jul; 37(32):4491-4498. PubMed ID: 31272872
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany.
    Kuhlmann A; von der Schulenburg JG
    Eur J Health Econ; 2017 Apr; 18(3):273-292. PubMed ID: 26905404
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness analysis of a universal mass vaccination program with a PHiD-CV 2+1 schedule in Malaysia.
    Wang XJ; Saha A; Zhang XH
    Cost Eff Resour Alloc; 2017; 15():17. PubMed ID: 28852326
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
    Steens A; Bergsaker MA; Aaberge IS; Rønning K; Vestrheim DF
    Vaccine; 2013 Dec; 31(52):6232-8. PubMed ID: 24176490
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness analysis of pneumococcal conjugate vaccines in preventing pneumonia in Peruvian children.
    Mezones-Holguín E; Bolaños-Díaz R; Fiestas V; Sanabria C; Gutiérrez-Aguado A; Fiestas F; Suárez VJ; Rodriguez-Morales AJ; Hernández AV
    J Infect Dev Ctries; 2014 Dec; 8(12):1552-62. PubMed ID: 25500653
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness evaluation of the 10-valent pneumococcal non-typeable
    Lu CY; Chung CH; Huang LM; Kruger E; Tan SC; Zhang XH; Chiu NC
    Cost Eff Resour Alloc; 2020; 18():30. PubMed ID: 32874139
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-Effectiveness of the Pneumococcal Conjugate Vaccine (10- or 13-Valent) Versus No Vaccination for a National Immunization Program in Tunisia or Algeria.
    Pugh SJ; Fletcher MA; Charos A; Imekraz L; Wasserman M; Farkouh R
    Infect Dis Ther; 2019 Mar; 8(1):63-74. PubMed ID: 30539417
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A cost-effectiveness analysis of pneumococcal conjugate vaccines in infants and herd protection in older adults in Colombia.
    Ordóñez JE; Ordóñez A
    Expert Rev Vaccines; 2023; 22(1):216-225. PubMed ID: 36812426
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to Higher-Valent Options in Greek Infants.
    Warren S; Barmpouni M; Kossyvaki V; Gourzoulidis G; Perdrizet J
    Vaccines (Basel); 2023 Aug; 11(8):. PubMed ID: 37631937
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Follow-up of serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae in child carriage after a PCV13-to-PCV10 vaccine switch in Belgium.
    Wouters I; Desmet S; Van Heirstraeten L; Blaizot S; Verhaegen J; Van Damme P; Malhotra-Kumar S; Theeten H;
    Vaccine; 2019 Feb; 37(8):1080-1086. PubMed ID: 30665775
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of routine childhood immunization with higher-valent pneumococcal conjugate vaccines on antimicrobial-resistant pneumococcal diseases and carriage: a systematic literature review.
    Tin Tin Htar M; van Den Biggelaar AHJ; Sings H; Ferreira G; Moffatt M; Hall-Murray C; Verstraeten T; Gessner BD; Schmitt HJ; Jodar L
    Expert Rev Vaccines; 2019 Oct; 18(10):1069-1089. PubMed ID: 31585049
    [No Abstract]   [Full Text] [Related]  

  • 37. Cost-effectiveness of new adult pneumococcal vaccination strategies in Italy.
    Boccalini S; Bechini A; Levi M; Tiscione E; Gasparini R; Bonanni P
    Hum Vaccin Immunother; 2013 Mar; 9(3):699-706. PubMed ID: 23295824
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An updated cost-effectiveness analysis of pneumococcal conjugate vaccine among children in Thailand.
    Dilokthornsakul P; Kengkla K; Saokaew S; Permsuwan U; Techasaensiri C; Chotpitayasunondh T; Chaiyakunapruk N
    Vaccine; 2019 Jul; 37(32):4551-4560. PubMed ID: 31280944
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of the ten- and thirteen-valent pneumococcal conjugate vaccines to prevent serotype 19A invasive pneumococcal disease in Quebec, Canada. A Canadian immunization research network (CIRN) study.
    Deceuninck G; Brousseau N; Lefebvre B; Quach C; Tapiero B; Bui YG; Desjardins M; De Wals P
    Vaccine; 2024 Dec; 42(26):126379. PubMed ID: 39332237
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Health Economic Impact of Universal Infant Vaccination with the 10-Valent Pneumococcal Nontypeable Haemophilus influenzae Protein D Conjugate Vaccine as Compared with 13-Valent Pneumococcal Conjugate Vaccine in Hong Kong.
    Lee KKC; Chia Wu DB; Topachevskyi O; Delgleize E; DeAntonio R
    Value Health Reg Issues; 2013 May; 2(1):64-74. PubMed ID: 29702855
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.